J&J’s Talvey combination cuts the risk of death by up to 53% in earlier-line multiple myeloma

Johnson & Johnson (NYSE: JNJ) announced Phase 3 MonumenTAL-3 results showing that its GPRC5D bispecific antibody Talvey (talquetamab-tgvs), combined with Darzalex Faspro (daratumumab and hyaluronidase) with or without pomalidomide, reduced the risk of disease progression or death by up to 72 percent and the risk of death by up to 53 percent compared with the standard regimen of Darzalex Faspro, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. The data, presented in a plenary session at the 2026 European Hematology Association Congress in Stockholm and simultaneously published in the New England Journal of Medicine, showed a 24-month progression-free survival rate of up to 81.3 percent versus 51.2 percent for standard care, and an overall survival rate of up to 89.2 percent versus 79.1 percent. This is the first Phase 3 study to demonstrate superior progression-free survival with a GPRC5D bispecific antibody combination in earlier-line multiple myeloma, and Johnson & Johnson has already submitted a supplemental Biologics License Application to the United States Food and Drug Administration and a Type II variation to the European Medicines Agency. The results matter because they push a powerful bispecific combination earlier into the treatment journey, strengthening Johnson & Johnson’s dominant position in multiple myeloma while expanding the addressable patient population for Talvey well beyond its current late-line use.

What did Johnson & Johnson’s MonumenTAL-3 trial show for Talvey in relapsed or refractory multiple myeloma?

The efficacy results were unusually strong for this disease setting. In patients who had received at least one prior line of therapy, the combination of Talvey plus daratumumab and pomalidomide cut the risk of progression or death by 72 percent, with a hazard ratio of 0.28, while the Talvey plus daratumumab doublet reduced that risk by 67 percent, and median progression-free survival was not reached in either Talvey arm against 24.4 months for the standard regimen. A hazard ratio that low in a randomized Phase 3 trial is a marker of a substantial treatment effect.

The competitive implication is that the survival benefit, not just the progression benefit, sets this data apart. Demonstrating up to a 53 percent reduction in the risk of death and a two-year overall survival rate near 89 percent is the kind of outcome that changes treatment guidelines, because overall survival is the gold-standard endpoint that payers and clinicians weigh most heavily. Many myeloma combinations improve progression metrics without clearly extending life, so a clear mortality benefit is differentiating.

The clinical context reinforces the significance. Multiple myeloma is the third most common blood cancer with more than 180,000 new cases diagnosed globally each year and a five-year survival rate near 60 percent, so a regimen that meaningfully extends both progression-free and overall survival addresses a serious unmet need. Importantly, the company reported that the safety profile was consistent with the known profiles of the individual medicines, which matters for a combination regimen where toxicity can limit adoption.

Why does moving the Talvey and Darzalex Faspro combination to earlier-line therapy matter strategically?

The strategic value lies in the shift earlier in treatment. Talvey is currently used in heavily pretreated, late-line patients, a relatively small population, and demonstrating superiority in patients with only one prior line of therapy opens the door to a far larger group of patients earlier in their disease course. Earlier-line approval dramatically expands the commercial opportunity.

The competitive implication is that Johnson & Johnson is extending its multiple myeloma franchise deeper into the treatment paradigm. The company already commands a leading position with daratumumab, the CAR-T therapy Carvykti, and the bispecific Tecvayli, and adding an earlier-line Talvey combination lets it defend and expand share across more lines of therapy. Owning multiple mechanisms across the treatment journey creates a franchise that is difficult for competitors to dislodge.

The risk is that earlier-line use raises the bar on tolerability and convenience. Patients treated earlier often have more therapeutic alternatives and longer expected treatment durations, so side-effect management and administration burden become more important, and bispecific antibodies carry distinctive safety considerations. The data showing a manageable safety profile is encouraging, but real-world adoption earlier in treatment will test whether the benefit-risk balance holds outside a trial setting.

How do the FDA and EMA regulatory filings position Talvey for a label expansion in multiple myeloma?

The regulatory machinery is already in motion. Johnson & Johnson has submitted a supplemental Biologics License Application to the United States Food and Drug Administration and a Type II variation to the European Medicines Agency, signaling that the company intends to convert this data into an expanded label as quickly as possible. Filing concurrently in both major markets reflects confidence in the strength of the results.

The competitive implication is a potential first-mover advantage for a GPRC5D bispecific in earlier-line combination use. Being first to demonstrate and file for superior progression-free survival with this mechanism in earlier disease could give Johnson & Johnson a meaningful lead before rivals advance competing combinations, and plenary presentation plus simultaneous publication in a top medical journal strengthens the case with regulators and prescribers. Scientific validation at this level supports both approval and adoption.

The risk is the usual regulatory and timing uncertainty. Supplemental filings still face review timelines, potential requests for additional analyses, and the possibility of label restrictions, and the accelerated enthusiasm at a conference does not guarantee a swift or unrestricted approval. The path from positive Phase 3 data to a broad commercial label remains subject to regulatory judgment in each jurisdiction.

What does the MonumenTAL-3 data mean for Halozyme and the broader multiple myeloma competitive landscape?

The data carries a clear read-through to Halozyme (NASDAQ: HALO). Darzalex Faspro relies on Halozyme’s subcutaneous drug-delivery technology, so wider and earlier use of Darzalex Faspro in combination regimens supports Halozyme’s royalty stream, making the company an indirect beneficiary of stronger daratumumab-based combinations. Royalty-based exposure to a blockbuster franchise expanding into earlier lines is a favorable position.

The competitive context is an intensifying race in multiple myeloma mechanisms. The field spans BCMA-targeted bispecifics and CAR-T therapies as well as the GPRC5D approach that Talvey represents, and Johnson & Johnson competes both against rivals and, in some respects, across its own portfolio, so demonstrating that a GPRC5D combination works earlier helps define how these mechanisms will be sequenced. The combination also incorporates pomalidomide, underscoring how modern myeloma regimens stack multiple agents.

The risk is that competitive and pricing pressures intensify as more effective combinations crowd the market. Highly effective multi-drug regimens raise the cost of care and invite payer scrutiny, and as competitors advance their own bispecific and cell-therapy combinations, differentiation will hinge on survival data, safety, and convenience. The myeloma market is becoming more crowded even as outcomes improve, which pressures pricing and share over time.

What should investors weigh on Johnson & Johnson given Talvey’s role within its larger myeloma franchise?

For Johnson & Johnson, the data is strategically meaningful but financially incremental in the immediate term. The announcement came on a Saturday at a medical conference, so there was no immediate trading reaction, and as a diversified healthcare company with a market value in the hundreds of billions, Johnson & Johnson’s stock is driven by its entire pharmaceutical and medtech portfolio rather than any single product. Talvey is a smaller contributor within a multiple myeloma franchise anchored by daratumumab.

The competitive case is that the data reinforces the durability of one of Johnson & Johnson’s most important growth franchises. Multiple myeloma is a large and growing market, and extending leadership across more lines of therapy supports the long-term revenue trajectory of the oncology business, which helps offset patent and litigation pressures elsewhere in the portfolio. Franchise depth is a meaningful long-term value driver.

For investors, the practical takeaway is that this is a positive proof point for Johnson & Johnson’s oncology strategy and a cleaner near-term read-through for Halozyme’s royalty economics than for Johnson & Johnson’s own shares. The prudent stance is to view the result as strengthening the long-term myeloma franchise and supporting the case for Talvey’s label expansion, while recognizing that the financial impact will build gradually through regulatory approval and adoption rather than appearing as an immediate catalyst. As always, this is general analysis rather than investment advice.

Key takeaways on what the Talvey trial data means for Johnson & Johnson, Halozyme, and oncology investors

• The MonumenTAL-3 Phase 3 trial showed Talvey combinations cut the risk of progression or death by up to 72 percent and the risk of death by up to 53 percent in relapsed or refractory multiple myeloma.
• Two-year progression-free survival reached up to 81.3 percent versus 51.2 percent for standard care, with overall survival up to 89.2 percent versus 79.1 percent.
• This is the first Phase 3 to show superior progression-free survival with a GPRC5D bispecific combination in earlier-line myeloma, a clear differentiator.
• The clinically meaningful overall survival benefit, not just the progression benefit, is what makes the data potentially guideline-changing.
• Moving Talvey from late-line to earlier-line use dramatically expands its addressable patient population and commercial opportunity.
• Johnson & Johnson has already filed a supplemental application with the FDA and a Type II variation with the EMA, signaling a fast push to expand the label.
• The result strengthens Johnson & Johnson’s leading multiple myeloma franchise alongside daratumumab, Carvykti, and Tecvayli.
• Halozyme is an indirect beneficiary, since wider Darzalex Faspro use supports its subcutaneous delivery royalty stream.
• The data is strategically important but financially incremental near term for a company of Johnson & Johnson’s scale, with no immediate market reaction given the Saturday announcement.
• A more crowded, more effective myeloma market will intensify pricing and competitive pressure even as patient outcomes improve.